Prana completes Ph IIa enrollment of PBT2 in AD

Melbourne, Australia-based Prana Biotechnology says it has completed patient enrollment in its Phase IIa clinical trial of PBT2 in patients with early Alzheimer's disease.

This is a double-blind, placebo-controlled study exploring the safety and tolerability of PBT2, Prana's proprietary lead compound, and its effects on the mechanism and progression of the disease by investigating biomarkers of AD as well as measures of cognition. Prana will complete dosing of the last patient by the end of this year, and is on track to deliver results in the first quarter of 2008.

"The successful completion of patient enrollment in this clinical trial represents an important milestone in the development of PBT2, particularly with the recruitment of patients now closed and a clear time line for the release of results," commented Prana chief executive, Geoffrey Kempler.